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Abstract
Background: Protein-protein interaction networks and phenotype similarity information have been synthesized
together to discover novel disease-causing genes. Genetic or phenotypic similarities are manifested as certain
modularity properties in a phenotype-gene heterogeneous network consisting of the phenotype-phenotype
similarity network, protein-protein interaction network and gene-disease association network. However, the
quantitative analysis of modularity in the heterogeneous network and its influence on disease-gene discovery are
still unaddressed. Furthermore, the genetic correspondence of the disease subtypes can be identified by marking
the genes and phenotypes in the phenotype-gene network. We present a novel network inference method to
measure the network modularity, and in particular to suggest the subtypes of diseases based on the
heterogeneous network.
Results: Based on a measure which is introduced to evaluate the closeness between two nodes in the
phenotype-gene heterogeneous network, we developed a Hitting-Time-based method, CIPHER-HIT, for assessing
the modularity of disease gene predictions and credibly prioritizing disease-causing genes, and then identifying the
genetic modules corresponding to potential subtypes of the queried phenotype. The CIPHER-HIT is free to rely on
any preset parameters. We found that when taking into account the modularity levels, the CIPHER-HIT method can
significantly improve the performance of disease gene predictions, which demonstrates modularity is one of the
key features for credible inference of disease genes on the phenotype-gene heterogeneous network. By applying
the CIPHER-HIT to the subtype analysis of Breast cancer, we found that the prioritized genes can be divided into
two sub-modules, one contains the members of the Fanconi anemia gene family, and the other contains a
reported protein complex MRE11/RAD50/NBN.
Conclusions: The phenotype-gene heterogeneous network contains abundant information for not only disease
genes discovery but also disease subtypes detection. The CIPHER-HIT method presented here is effective for
network inference, particularly on credible prediction of disease genes and the subtype analysis of diseases, for
example Breast cancer. This method provides a promising way to analyze heterogeneous biological networks, both
globally and locally.
Background
D i s e a s eg e n ep r e d i c t i o ni so n eo ft h em o s ti m p o r t a n t
aims in biological and medical sciences. Network-based
evidence as well as inference approaches has become
more and more attractive in the research field of
disease-causing gene discovery, and a variety of methods
have been developed recently from this point of view
[1-5]. Researchers also attach great importance to spe-
cial features embedded in biological networks especially
the protein-protein interaction (PPI) network for deeply
understanding molecular mechanism of common
human diseases [6-15]. Since genetic diseases are geneti-
cally or phenotypically similar, it is promising to com-
bine the protein-protein interactions and the phenotype
similarities to a phenotype-gene heterogeneous network
to infer the candidate disease genes [1-4]. The so-called
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any medium, provided the original work is properly cited.“phenotype-gene heterogeneous network” reflects a hol-
istic view of complex relationships among various phe-
notypes and phenotypes, phenotypes and genes, as well
as genes and genes, which consists of the phenotype-
phenotype similarity network, gene-disease association
network and protein-protein interaction network,
respectively. Based on such a heterogeneous network,
we propose a regression model named CIPHER (Corre-
lating protein Interaction network and PHEnotype net-
work to pRedict disease genes) to quantify the
concordance between candidate genes and target pheno-
types [2]. The algorithm of random walk is also pro-
posed to prioritize the candidate disease genes in
protein-protein interaction networks [3] and then a ran-
dom walk with restarts (RWR) method is extended to
the above heterogeneous network [4].
In general, the network-based disease-gene discovery
methods make use of information from both the topolo-
gical structure and the associations between diseases and
genes. The basic assumption is that similar disease phe-
notypes are caused by functionally related genes and
these genes are likely to be close to each other on the
protein-protein interaction networks, so that network
modules are formed [15-18,5]. Here the network module
in computation refers to a group of genes exhibiting net-
work proximity, and in biology refers to certain func-
tional units such as protein complexes, signaling or
metabolic pathways and transcriptional programs
[16-19,5]. Therefore, the algorithms in [3] prioritize can-
didate genes based on their closeness to known disease
genes. After the similarity information between the phe-
n o t y p e si sp r o v i d e db yv a nD r i e let al. through text
mining technology [17], the phenotype similarity and the
protein-protein interactions are combined together for
the prioritization of the candidate disease genes [1,2,4].
However, so far little modularity analysis on the phe-
notype-gene heterogeneous networks has been done.
The predicted results from the network inference meth-
ods need to be tested to see whether they form the
modules and to which corresponding biological function
they are related. In this paper, the network inference
methods are further developed to measure the modular-
ity property of the disease-gene prediction results.
Furthermore, we also provide the method to infer the
relationship between the subtypes of diseases and the
modules formed by these predicted results.
Inference on the phenotype-gene heterogeneous network
For the network-based inference, a candidate gene g is
prioritized to be a potential disease-causing gene of the
target phenotype p if one or both of the followings are
satisfied:
1. The gene g is close to some disease-causing genes
associated with p.
2. The gene g is close to some phenotypes which are
highly similar to p.
Hence one key point is to define the closeness
between two nodes in the network, and this will be used
to measure the similarity between the nodes based on
the network topology [1,2]. Currently the nearest-neigh-
bor method considers the direct interactions informa-
tion and ignores the long-range interactions. The
shortest-path method considers the length of the short-
est path connecting two nodes but ignores the number
of short paths between them. The random walk with
restart method [3,4] combines the local and global net-
work information to enhance the prediction
performance.
Another key point is the priori information known
about each target phenotype, the known disease-genes
and the similar phenotypes. In the phenotype-gene het-
erogeneous network, for each given phenotype p,i t s
known causing genes and the similar phenotypes are
represented as the nodes which link to p directly, and
these nodes are termed as the adjacent nodes of the tar-
get phenotype p in the heterogeneous network. The
paths between p and any other nodes have to cross this
adjacency set. Therefore, the prioritization can be car-
ried out by measuring the closeness between the candi-
date genes (namely all genes in the protein-protein
interaction network) and these adjacent nodes.
In this paper, we introduced a closeness measure
based on the methods of Mean-Hitting-Time and condi-
tional Mean-Hitting-Time, which not only capture the
global relationships within the phenotype-gene heteroge-
neous network, but also free to rely on any priori para-
meters. Moreover, by studying the different relationships
to different adjacent nodes, we assume that the priori-
tized genes can be further divided into sub-modules
which may correspond to the subtypes of the disease.
And the conditional Mean-Hitting-Time can be applied
to discover such disease subtypes. The present Hitting-
Time-based method with the flowchart illustrated in
Figure 1 is called CIPHER-HIT, as a continuation of our
CIPHER method [2].
Candidate disease genes prioritization: which are the
most credible?
Based on the closeness measure of the phenotype-gene
heterogeneous network, the candidate genes can be
prioritized according to their topological similarities of
the adjacent nodes. The inference is of the same spirit
as the methods in [1-4]. However, some disease-causing
genes are likely to be topologically similar, whereas
some others will be dispersed among the heterogeneous
network. As shown in Figure 1, for a phenotype that has
many known disease genes and similar phenotypes, we
probe the relationships among these adjacent nodes and
Yao et al. BMC Systems Biology 2011, 5:79
http://www.biomedcentral.com/1752-0509/5/79
Page 2 of 11suppose that if an adjacent node (a known disease gene
or a similar phenotype to the target phenotype) has
higher topological similarity with the others, then it will
be a more credible reference gene or phenotype for
inference of disease-causing genes. Here the topological
similarity between two nodes means their closeness or
connectivity strength on the network, which can be
defined as the Mean-Hitting-Time of the random walk.
We consider this hypothesis is reasonable since it is
widely assumed that similar phenotypes may be caused
by functionally close related genes [15,16], thus if more
information about protein-protein interactions, gene-
phenotype associations as well as phenotype-phenotype
similarities is known, higher inference accuracy in gene-
phenotype relationship inference will be achieved. As a
graphic illustration shown in Figure 2, nodes u1, u2 and
u3 w i l lb et h em o r ec r e d i b l er e f e r e n c e st h a nu4 since
they are close to each other. Therefore, our CIPHER-
HIT method developed is firstly used to measure the
connectivity strength between one adjacent node and
the others, and then those candidate genes near the
credible reference will be marked as the ones being
more likely to form modules in the network.
Gene sets inference for the disease subtypes
Identifying subtypes of diseases such as cancer is of cri-
tical importance for predicting clinical outcomes as well
as designing more-specific therapies for patients,
Figure 1 The flowchart of the CIPHER-HIT method. In the CIPHER-HIT method, we first evaluate the modularity of the adjacent nodes around
the given phenotype, and then select credible reference for disease gene prediction by the Mean-Hitting-Time, which will be further subjected
to detection of disease subtypes by the conditional Mean-Hitting-Time on the phenotype-gene heterogeneous network.
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sonalized medicine [20,21]. The intrinsic cancer sub-
types have been studied in different ways by using
histology, molecular pathology, genetic mutation and
gene-expression information [21]. The classification of
human cancer has become more and more informative
as the detailed molecular analysis is provided. For exam-
ple, the molecular heterogeneity in tumor can be recog-
nized according to the different patterns of the gene
expression information [20-22]. Interestingly, Li et al.
recently reported an integrative network analysis
method to identify recurrent network modules that con-
tribute to Breast cancer metastasis by using a set of
tumour gene microarrays [23]. Since molecular network
modules have been detected in cancer subtypes [23], it
is possible to use network modules to further classify
Breast cancer into subtypes.
It is well accepted that similar phenotypes may be
caused by functionally close related genes [1-16]. An
extension of this assumption would be that genes
related to different subtypes are likely to form distinct
protein-protein interaction modules, which is a common
indicator of gene functional relationship [24].
Thus, our CIPHER-HIT method is further used to
identify the sub-groups of genes corresponding to the
cancer subtypes. Such groups of genes are called sub-
modules in the network, and the main task of our
method is to identify the gene sets related to different
subtypes of a target disease (or phenotype). In cases
where the heterogeneity information of a phenotype is
included in its adjacent nodes, it is promising to further
classify the prioritized genes based on such information.
The similar phenotypes and their associated genes have
also provided information for identifying the sub-mod-
ules. For example, the phenotype node representing
FANCONI ANIMIA has high topological similarity to
the phenotype node BREAST CANCER. Recent studies
demonstrate that genes FANCA, FANCB, FANCC,
FANCD2, FANCE, FANCF and FANCG associated with
Fanconi animia are closely related to the susceptibility
of Breast cancer [25,26]. These genes can be prioritized
to be associated with Breast cancer by CIPHER-HIT
successfully. In addition, by discriminating the adjacent
nodes through which these genes are prioritized, they
can also be marked as the sub-module corresponding to
the subtype of Fanconi animia related Breast cancer.
Thus, in this work, we develop a method to reveal the
relationship between each prioritized gene and each adja-
cent node so that the hierarchical clustering method is
applied to discover the potential subtypes of the target
phenotype. These results are meaningful for further bio-
medical and experimental researches, since they help to
focus on the genes which are likely to form the sub-mod-
ules corresponding to the potential subtypes of diseases.
Results and Discussion
CIPHER-HIT: the topological closeness measure based on
the Mean-Hitting-Time
T h eC I P H E Rm e t h o d[ 2 ]a n dt h er a n d o mw a l kw i t h
restart method (RWR) [3,4] are the approaches which
reflect the global structural information of the pheno-
type-gene heterogeneous network, while the parameters
such as the restart rate in RWR, which are related to
the performance, are required to be pre-set. In the
CIPHER-HIT method, we present a new closeness mea-
sure between two nodes based on the Mean-Hitting-
Time of the random walk on the heterogeneous net-
work. Although this measure is developed from the
same mathematical background as the random walk
with restart method [3,4], it both reflects the global
topological information very well and refrains from set-
ting up a difficult-to-explain priori parameter. Moreover,
one extension of this measure - the conditional Mean-
Hitting-Time can be used to discover modularity char-
acteristics on the phenotype-gene heterogeneous net-
work and contribute to disease subtype inference.
For a random walk on the network, the Hitting-Time to
the set of nodes B, denoted by τB, is defined as the first time
when B is visited. The Mean-Hitting-Time of a random
walk starting from the node a to the set B is defined as
EaτB =  ∞
k=0 kPa(τB = k) (1)
where ℙa(τB = k) refers to the possibility that a ran-
dom walk starting form node a hits the set B at a time
Figure 2 Illustration of the network inference and modularity
measure in CIPHER-HIT. The circle nodes represent the genes and
the rectangle nodes represent the phenotypes. The red node
denotes the target phenotype p. The yellow nodes (u) denote the
adjacent nodes of p, i.e. the set Ep, referring to either genes or
phenotypes. (A) The dashed ellipses enclose the adjacent nodes
which share high topological similarity. The nodes u1, u2 and u3 are
close to each other. Therefore candidate nodes g1, g2, g3 and g4,
which can more easily form a module in the protein-protein
network, will be prioritized as the potential disease-genes. The
group u1, u2 u3, g1, g2, g3 and g4 will be inferred as a module
related to phenotype p. (B) The illustration of the meaning of the
conditional Mean-Hitting-TimeEg(τp|τp <τ Ep\{ui}). Among the
paths from the candidate genes g to the phenotype p, the
influence of the paths passing the adjacent nodes other than u1 are
excluded, which are illustrated as dashed lines.
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positive infinite.
The Mean-Hitting-Time include all the router infor-
mation between the node a and set B.W ed e f i n et h e
closeness measure between node a and set B by the
scaled Mean-Hitting-Time (MHT) with the maximal
value for all nodes a’ on the network,
MHT(a,B)=
Ea(τB)
maxa Ea (τB)
(2)
Here Ea(τB) can be inconveniently large in actual cal-
culation, so we scale it to ensure the range of MHT is
between 0 and 1.
Furthermore, if we need a topological closeness
between the node a and the set B without the influence
of a given set of nodes, A, the conditional Mean-Hit-
ting-Time will be a natural choice. It is defined as
Ea(τB|τB <τ A)= ∞
k=0kPa(τB = k|τB <τ A) (3)
where ℙa(τB = k|τB <τA) refers to the possibility that a
random walk starting form node a hits the set B at a
time point k, conditioning on the same random walk
hits the set B before it hits the set A.
Similarly, we define the scaled conditional Mean-Hit-
ting-Time (CMHT) CMHT(a, B|A), as the closeness
measure between node a and set B, without the influ-
ence of set A,
CMHT(a,B|A)=
Ea(τB|τB <τ A)
maxa  ∈AEa (τB|τB <τ A)
(4)
We also scale CMHT to the range between 0 and 1 to
avoid the inconvenient large Ea(τB|τB <τ A) in actual
calculation. Both of the closeness measures defined in
Equation (2) and Equation (4) can be computed expli-
citly without any preset parameters (see detailed compu-
tational methods in Material and Methods).
Performance of CIPHER-HIT in credibly predicting
diseases-causing genes
In this work, we firstly apply the scaled Mean-Hitting-
Time in ranking candidate disease-causing genes based
on the phenotype-gene heterogeneous network. The
adjacency set of a certain node n on the network is
defined as all those nodes linked to n by an edge on the
network, either a 1-valued association as in the protein-
protein interaction network and gene-disease association
network, or a positively weighed association as in the
phenotype-phenotype similarity network filtered by a
threshold (see Material and Methods). For each given
phenotype p having an adjacency set Ep = {u1,···,um},
we compute MHT(g,{p}) for each candidate gene g. After
ranking MHT(g,{p}) from the smallest to the largest, a
gene g will be prioritized as the potentially causal gene
associated with phenotype p if MHT(g,{p}) <θR,w h e r eθR
is the filtering threshold. The detailed setting of θR will
be discussed at middle of the second to last paragraph of
this subsection. The ranking information of each gene g
is recorded as the ranking position RANKp(g). For the
target phenotypes p which have many nodes in the adja-
cency set Ep,w ei n t r o d u c et h eM o d u l a r i t yL e v e lt h r o u g h
conditional Mean-Hitting-Time as below:
Mp(ui) = minu∈εp\{ui}CMHT(u,{ui}|{p}), i =1 ,···,m, (5)
which can be used to test the connectivity strength
between ui and other adjacency nodes. Note that a smal-
ler value of the conditional Mean-Hitting-Time (Mp(ui))
indicates a higher modularity level, namely a stronger
connection between the adjacent node (ui)a n do t h e r
nodes in the adjacency set (Ep\{ui}). By calculating the
minimum conditional Mean-Hitting-Time, we assess the
modularity level of one node p on the network with
regard to its adjacency node ui as the maximum connec-
tivity strength between other adjacency nodes u and ui.
Different from the concept of topological similarity
between two nodes, the modularity level of one node
with regard to another takes the other adjacency nodes
into consideration, and serves as the measure of connec-
tivity strength among more than two connected nodes.
Then we set a threshold θM to distinguish the adjacent
nodes so that ui ∈ Ep which satisfies Mp(ui)< θM will be
marked as the one with high connectivity strength to
the other adjacent nodes.
Hence the adjacent nodes are divided into two parts,
E 
p and E  
p which are defined as
E 
p = {u ∈ Ep : Mp(u) ≤ θM}, (6)
E  
p = {u ∈ Ep : Mp(u) >θ M}. (7)
According to the definition above, E 
p denotes the
adjacent nodes u including disease-genes associated with
p or phenotypes similar to p that are strongly connected
with each other. For any ui,uj ∈ E 
p,t h er a n d o mw a l k
starting from ui will reach uj easily without passing p.
This feature is illustrated in Figure 2B.
Next, we analyze the prioritized genes for target phe-
notype p. We measure the closeness between each gene
to the nodes in E 
p without the influence of the nodes in
E  
p. We compute CMHT(g,E 
p |E  
p) for each gene g and
then rank results from the smallest to the largest, so
that we record the ranking position r’p(g). By compari-
son of RANKp(g)a n dR A N K ’p(g) for each prioritized
genes, and if RANKp(g)/RANK’p(g)>1 ,w ec o n c l u d e
that gene g is in association with the node p because it
is close to the adjacent nodes in set E 
p, and these genes
are marked as the most credible predicted results.
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genome-wide leave-one-out cross-validation. The candi-
date gene set is defined as all genes on the heteroge-
neous network. The set of validated genes are the
known associated genes of the disease phenotypes. At
each round of the validation, one gene associated with
the target phenotype will be chosen as a validated sam-
ple, the link between the chosen gene-node and the
phenotype-node is removed and the scaled Mean-Hit-
ting-Time from each gene-node to the target pheno-
type-node (the one from which a link is removed) is re-
computed and ranked from the smallest to the largest.
Note that a disease gene can be associated with many
phenotypes. Therefore, the gene is deemed to come
from different samples when the validation is carried
out for different phenotypes. If a sample for validation
satisfies MHT(g,{p}) <θR, it will be considered a success-
ful prediction. The results of the leave-one-out cross
validation are shown as the receiver operating character-
istic (ROC) curves in Figure 3, where the horizontal
coordinates (1-Specificity) refer to values of θR,a n dt h e
vertical coordinates (Sensitivity) refer to the true-posi-
tive rate corresponding to θR. The validation on the dis-
ease genes in the set E  
p produces obviously poorer
performance than the validation on the disease genes in
the set E 
p. This is reasonable since the genes in E 
p are
likely to be close to the other known disease genes or
phenotypes similar to p. From the results shown in Fig-
ure 3A, we found that the higher the modularity level a
gene to the other adjacent nodes is, the higher the suc-
cessful rate of the validation will be. When compared
with the random walk with restarts (RWR) method [4],
we found that the ROC curves of both RWR and
CIPHER-HIT are comparable. However, when taking
into account the modularity levels, only the adjacent
node u of Mp(u)< θM =0 . 3a r eu s e df o ri n f e r e n c ei n
CIPHER-HIT method, the so-called modular CIPHER-
HIT can significantly improve the performance of dis-
ease gene predictions, making it possible to reach the
credible prediction of disease genes (Figure 3B).
Note that though we mark the prioritized genes that
are close to the adjacent node in Ep, we do not exclude
the other prioritized genes. The nodes in E  
p are also
available to form modules with other genes but they
might not be exhibited because of the incompleteness of
the network information. Since the genes in E 
p already
exhibit the inclination to have tight relationship, we sug-
gest the marked genes be selected for further biological
investigation with high priority.
Disease subtype inference by CIPHER-HIT
The development of a reliable method to identify disease
subtypes will not only enhance our understanding of
disease mechanism, but also provide principles for design-
ing a tailored diagnosis and treatment for patients. For a
long time, identification of disease subtypes by phenotype
associations of patients is of highly importance for assign-
ing individual treatments in the medical community, espe-
cially in traditional Chinese medicine which holds “Bian-
ZHENG-Lun-Zhi“ (Syndrome differentiation and treat-
ment for disease) as its core concept [27]. Inspired by such
a rationale [27], we further note that in the heterogeneous
networks, the adjacent set of a target phenotype can be
used not only to predict potential disease-causing genes,
but also to reveal further structural relationships among
the genes with regard to their contributions to disease
phenotypes. If the prioritized genes of a query phenotype
can be further grouped into several classes according to
different functions, then the sub-modules in the network
Figure 3 Results of the genome-wide cross-validation for
disease gene prioritization. (A) The conditional Mean-Hitting-Time
(Mp(g)) is calculated by Equation (5). Results showed that genes with
high modularity levels to the other adjacent nodes with small Mp(g)
values will be more likely to be successfully prioritized during the
validation. (B) The receiver operating characteristic (ROC) curves of
the genome-wide leave-one-out cross-validation. The horizontal
coordinates (1-Specificity) refer to values of θR, while the vertical
coordinates (Sensitivity) refer to the true-positive rate corresponding
to θR. The red solid line denotes the inference of modular CIPHER-
HIT based on the nodes in E 
p, i.e. only the adjacent node u of Mp
(u)< θM = 0.3 are used for inference. The dashed lines both denote
the inference based on the nodes in E  
p, i.e. only the adjacent node
u of Mp(u) ≥ θM = 0.3 are used for inference, where the blue
dashed line denotes results from the random walk with restarts
(RWR) method, and the red dashed line denotes results from the
CIPHER-HIT method.
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sub-groups of genes.
Thus, in the framework of CIPHER-HIT, given a
queried phenotype p, suppose its adjacent node and
prioritized gene set are {u1,· · · ,um}a n d{ g1,· · · ,gk},
respectively, then we define
cp(g,ui)=C M H T ( g,{ui}|Ep\{ui}),i =1 ,··· ,m, (8)
which measures the closeness between the gene g and
the adjacent node ui without the influence of the other
adjacent nodes. Note that the selection of prioritized
genes set {g1, ···, gk} here is addressed by fitting a thresh-
old θR in the step of disease gene prioritization. Since
we filter credible disease gene set by the Mean-Hitting-
Time MHT(g,{ p}), we naturally choose the threshold as
the critical point of the empirical distribution function
of MHT(g,{ p}) for all genes on the network (See case
study for Breast cancer). Then, as shown in Figure 2B,
the value cp(g, u1) will only depend on the path connect-
ing gene g and p trough the adjacent node u1, without
considering the paths passing other adjacent nodes u2,
u3, ···. After computing cp(g, ui) for all the adjacent
nodes of p, we can get feature vectors of the prioritized
genes g. By the alignment of such feature vectors of all
the prioritized genes, we obtain the following matrix
C=
⎡
⎢
⎣
cp(g1,u1) ···cp(g1,um)
. . .
...
. . .
cp(gk,u1) ···cp(gk,um)
⎤
⎥
⎦ (9)
Next, the classification of the prioritized genes can be
done by diagonalization of the matrix C in Equation (9)
by using the hierarchical clustering method. Further-
more, after matrix diagonalization, suppose the genes
are divided into groups G1, G2 ···,Gl, and the adjacent
nodes are divided into Ep,1,Ep,2,···,Ep,k,t h e ni ti sp r o -
mising to analyze the subtypes of the phenotype p based
on such divisions. And the resulted sub-groups of dis-
ease genes are likely to be related to the functional units
of disease subtypes.
Finally, we statistically analyze the subgroups of genes
to evaluate whether they are separable in terms of net-
work topology. We calculate the Mean-Hitting-Time
between pairs of predicted disease-causing genes, either
w i t h i nt h es a m es u b g r o u po r between different sub-
groups, to assess the topological similarity. The Fisher’s
exact test [28] is employed to access whether gene pairs
within the same subgroup are more topologically similar
than gene pairs in separate subgroups.
A case study on Breast cancer subtype detection
Breast cancer is known to be a carcinoma with highly
heterogeneous [21] and its heterogeneity is more com-
plicate than the results suggested by histopathological
analysis alone [29], so it became necessary to find more
molecular evidence to distinguish Breast cancer sub-
types. Therefore, we take “Breast cancer” as a typical
case to evaluate the performance of CIPHER-HIT for
detection of disease subtypes.
As shown in Figure 4A, the credible disease genes for
Breast cancer predicted by CIPHER-HIT were filtered
by the critical point of threshold θR =0 . 9 6a n dr e s u l t e d
in a total of 155 credibly prioritized genes. Interestingly,
by classification of the adjacent vectors described above,
w ef o u n dt h a ti ti sw o r t h w h i l et on o t et h a t5 3o ft h e
prioritized genes of Breast cancer can be divided into
two groups (Figure 4B and 4C). The group containing
the members of the Fanconi anemia gene family are
tightly connected to the phenotypes FANCONI ANE-
MIA (OMIM ID: 227650), ATAXIA TELANGIECTA-
SIA (OMIM ID: 208900), BREAST CANCER 1 GENE
(OMIM ID: 113705), XERODERMA PIGMENTOSUM
(OMIM ID: 278700) and the disease gene BRCA2.
Another group is tightly related to the disease genes
BRIP1, BRCA1, NBN and RAD51. BRCA1 is shared by
both groups. In addition, the adjacent nodes of Breast
cancer are divided into two parts, each of which leads to
a sub-group of genes representing a subtype of Breast
c a n c e r .T h et w os u b t y p e sw i t hg e n e so b t a i n e db yt h e
predictions of CIPHER-HIT not only have significant
difference in topological features by Fisher’se x a c tt e s t
(P < 0.0001 for both subtypes, see Table 1), but also
yield agreements with the evidence reported by recent
studies [25,26,30-34]. For example, the genes RAD50
and MRE11A in one of the predicted sub-groups are
reported to form a protein complex related to Breast
cancer [30]. Moreover, genes in the other predicted sub-
group consist of FANCA, FANCB, FANCC, FANCD2,
FANCE, FANCF and FANCG, which belong to the Fan-
coni anemia gene family, have been shown to be risk
breast cancer susceptibility genes and contribute signifi-
cantly to breast cancer predisposition [25,26]. The
importance of genes involving in this subtype of Breast
cancer is also supported by recent studies. For example,
the polymorphisms of CYP19A1 (the aromatase gene)
are closely related to the status and expression levels of
estrogen receptor (ER) [31-33], HER2/neu [34] as well
as progesterone [35]. Therefore, we suggest that the
subtypes predicted by our method may serve as impor-
tant genetic determinants that can influence the devel-
opment of the well-known subtypes of breast cancer
such as ER positive/negative, HER2 positive/negative, or
progesterone receptor positive/negative [36,37].
Thus, the case study of Breast cancer shown in Figure 4
provides evidence that the connectivity features of the
phenotype-gene heterogeneous network can be used to
distinguish the molecular bases related to different dis-
ease subtypes and lead to novel findings. And the
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Page 7 of 11Figure 4 Two subtypes of Breast cancer detected by CIPHER-HIT. (A) The empirical distribution function of MHT(g,{p}) where p denotes the
BREAST CANCER and g denotes all genes on the network. The θR threshold = 0.96 at the critical point is selected in the Breast Cancer case. (B)
The rows represent the similar phenotypes and disease-genes associated with Breast cancer and the columns represent the prioritized genes.
The grey color indicates the closeness between an adjacent node and a prioritized node measured by the conditional Mean-Hitting-Time.
Therefore the prioritized nodes are divided into two clusters in which the gene names of the nodes are displayed by red and blue respectively.
(C) The yellow squares are the phenotypes with high similarity to Breast cancer and the yellow circles are the disease-genes associated with
Breast cancer. For a better illustration, we left out two phenotypes (P120435 and P176807) in (B) with no connections to other nodes in the
selected network. The blue and red circles denote two groups of prioritized genes by CIPHER-HIT. The module related to FANCONI ANEMIA
locates in the cluster colored red and we added such a phenotype FANCONI ANEMIA in the graph. The protein complex RAD50/MRE11A/NBN
locates in the cluster colored blue.
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Page 8 of 11CIPHER-HIT method could serve as an important com-
plementarity to current approaches for identification of
cancer subtypes. If the prioritized genes of a queried phe-
notype are further divided into sub-groups which are
related to subtypes of the disease, then we call each sub-
group of genes as the susceptible modules of disease
subtypes.
From the above example, it can be seen that the poly-
morphism of the cancer is related to a group of genes,
instead of a single gene. We propose to characterize the
subtypes of a disease by distinguishing the associated
gene groups. If the adjacent nodes of a given phenotype
exhibit a genetic or phenotypic difference, namely the
prioritized genes can be divided into several sub-groups
according to their relations to the adjacent nodes, it is
likely to reveal subtypes according to a sub-division.
Our work demonstrates that the disease subtype analysis
can be carried out in the network context and benefit
from the integration of phenotype and gene heteroge-
neous information. We also show that the modularity-
based method, CIPHER-HIT, is a promising way to dis-
cover the subtype-associated genes based on the hetero-
geneous network structure. Based on the prioritization
information on the gene sets, the results will allow for
further clinical and experimental researches.
For the limitations of the present work, the CIPHER-
HIT method currently only restricts on the genetic level,
makes use of relatively simple data resources, and does
not consider the quantitative analysis for gene expres-
sions. As one of the future research directions, more
efforts are still need to be made to evaluate the perfor-
mance our method on different data, especially include
quantitative information such as microarray and proteo-
mics data for discovering disease mechanism in the
gene expression level or protein level. An extension of
our method to the systematic identification of disease
subtypes also needs to be developed. Moreover, we
believe that the method can also be easily generalized to
enable the credible prediction of drug targets and detect
the pleiotropic effects of drugs in our drugCIPHER fra-
mework [38] if we combine drug targets information
into the phenotype-gene heterogeneous network.
Conclusions
In summary, in this work, we introduce a concept of
modularity level and propose a CIPHER-HIT method to
use the Mean-Hitting-Time to measure global closeness
between nodes of the heterogeneous network that con-
sists of both genes and phenotypes. This measure has
solid mathematics foundations and is easy to calculate.
Based on this measure, we proposed a method to select
high confident neighbors of a phenotype and detect
gene modules that are highly connected to these high
confident neighbors. Therefore the modularity of priori-
tized genes can be revealed, which may provide more
mechanistic insights to the phenotype-genotype associa-
tion. We also demonstrate that the performance of dis-
ease gene predictions is improved significantly by
combining the modularity measure into the network
inference, suggesting modularity is one of key features
for network-based credible prioritization of candidate
disease genes. Moreover, by detecting the sub-modules
in the heterogeneous network, we revealed the poten-
tially genetic and phenotypic properties of cancer sub-
types. We believe this method can also be explored to
predict biomarkers associated with disease subtypes in
the gene expression and protein levels, as well as detect
the pleiotropic drug actions in the future.
Materials and methods
Dataset and the heterogeneous network
We used the following three data sets to form the three
parts, namely the phenotype-phenotype similarity net-
work, protein-protein interaction network and gene-
disease association network, of the phenotype-gene
heterogeneous network based on which the prediction
was carried out.
￿ The Human Protein Reference Database (HPRD)
[39] was adopted to construct the protein-protein inter-
action network. The largest component of the HPRD
protein-protein interaction network contains 34364
edges and 8503 vertices.
￿ The phenotype similarity came from the results cal-
culated by van Driel et al. [17]. The phenotype similarity
network contains 5080 phenotypes.
￿ The associations between the phenotypes and genes
were from the OMIM (Online Mendelian Inheritance in
Man, http://www.ncbi.nlm.nih.gov/omim) records as
described in precious studies [2,4]. The edge weights of
this phenotype-gene sub-network will be defined in
Equation (10).
Table 1 Statistical measures for the predicted two
subtypes of Breast cancer*
Disease
subtypes
(Disease
subgroup)
Number of gene pairs
with high topological
similarity
MHT(g, g’)< θR)
Number of gene
pairs with low
topological
similarity
MHT(g, g’)> θR)
P value#
Within
subgroup 1
56 64 P1<0.0001
Within
subgroup 2
333 570 P2<0.0001
Between
subgroups
1 and 2
128 480
*: We assess the modularity level of the predicted disease subtypes by
comparing topological similarity of gene pairs within each subgroup to gene
pairs between the two subgroups.
#: The P value of disease subgroup 1 (P1) and the P value of disease subgroup
2( P 2) are calculated using the Fisher’s Exact Test.
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Page 9 of 11The heterogeneous network was described by the
weight matrix. We constructed it by merging the weight
matrices of the sub-networks into one matrix. Let WG
denote the weight matrix of the HPRD network. For any
two genes g1 and g2, if there was a corresponding pro-
tein-protein interaction recorded in the HPRD database,
then WG(g1, g2) = 1, otherwise WG(g1, g2)=0 .
The phenotype similarities were used as the descrip-
tion of the diseases relations. The same data as previous
works [2,4] were used, where the phenotype similarity
data were calculated by van Driel et al. [17]. Since the
high similarities were only present between parts of phe-
notype pairs, we set a threshold to filter out very low
similarity values. Let Wp denote the weight matrix of
the phenotype-phenotype similarity network. If the simi-
larity value between two phenotypes p1 and p2 was lar-
ger than the threshold 0.4, then the weight Wp(p1, p2)
took this similarity value, otherwise Wp(p1, p2)=0 .
The phenotype-gene associations were taken from the
same data set as [2,4]. If there was an association
between phenotype p And gene g, then we specified the
weight of the corresponding edge as
WA(g,p)=
 g ∼gWG(g,g )+ p ∼pWP(p,p )
2
(10)
by which we can achieve that for each pair of asso-
ciated gene and phenotype (g, p), the average possibility
of “walking” onto a different sub-network at the point g
and p in the random walk process will equal 0.5.
Thus, the weight matrix of the heterogeneous network
was constructed as
W=
 
WP WA
WT
A WG
 
(11)
where WT
A refers to the transpose of WA.
We defined the random walk according to the weight
matrix described as Equation (11) and carried out the
network inference on it.
The Mean-Hitting-Time and conditional Mean-Hitting-
Time in CIPHER-HIT
In the previous random walk with restart method [3,4], the
stationary distribution is used to define closeness between
two nodes on a network. Here we define the topological
properties on the phenotype-gene heterogeneous network
in the same mathematical background using the Mean-Hit-
ting-Time of the random walk. This definition is more sui-
table in solving the problem of both disease-causing gene
inference and disease subtype inference, because by adopt-
ing this measure, we no longer have to choose the priori
parameter required in the former method (which was
always assumed to be arbitrary), and this measure leads us
to a natural way of discovering modularity characteristics
on the heterogeneous network. The math formula expres-
sions below are mainly adopted from [40,41].
The random walk on the heterogeneous network was
constructed by specifying its transition probability matrix
P based on the weighted matrix W in Equation (11).
P(i,j)=
Wi,j
Wi
, where Wi =  jW(i,j) (12)
The Mean-Hitting-Time from other nodes to a given
node p could be obtained by solving the following Equa-
tion (13)
(I − P)x(ν)=1 , ν  = p
x(p) =0 , Otherwise,
(13)
where I refers to the identity matrix, and x(v) refers to
the vth component of vector x.
T h en o n - n e g a t i v em i n i m u ms o l u t i o n
{x(ν)=Eν(τp):ν ∈ V} gave the Mean-Hitting-Time
from all other nodes, both the gene-nodes and pheno-
t y p e - n o d e s ,t ot h eg i v e np h e n o t y p e - n o d ep.F u r t h e r -
more, the conditional Mean-Hitting-Time
Eν(τp|τp <τ B) could be computed by solving
(I − P)y(ν)= Pν(τp <τ B), ν  ∈ B ∪{ p};
y(ν) =0 , Otherwise,
(14)
where ℙv(τp <τB), termed as the harmonic potential in
the Markov Process theory, is the probability that a ran-
dom walk starting from v reached p before B. The har-
monic potential could also be obtained from the
minimum non-negative solution of
(I − P)z(ν)=0 ; ν  ∈{ p}∪B
z(p)=1 ,
z(ν) =0 , ν ∈ B
(15)
The theoretical proof of Equations (13), (14), and (15)
is referred to [40,41].
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